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Abstract In this single-centre retrospective case
review, we investigate the long-term follow-up of
birdshot retinochoroiditis (BRC) patients, analysing
the impact of early, vigorous, and prolonged treatment
on the evolution of indocyanine green angiography
(ICGA) signs and fundus appearance. Treatment delay
was calculated for each BRC patient, and patients
were classified into two groups—treatment delay of
\10 months (early-treatment group) and treatment
delay of [10 months (delayed-treatment group).
Fundus photographs and ICGA frames from the initial
visit and from the last follow-up visit were assessed.
Fundus photographs were evaluated for the presence
of at least three circumpapillary, typical, rice-shaped
birdshot lesions in one eye, inferior or nasal to the
optic disc. ICGA pictures were evaluated for the
presence of lesions (hypofluorescent dark dots, fuzz-
iness). Differences were compared between the two
groups and between the first visit and the last follow-
up visit. In the early-treatment group, 5/6 patients had
no characteristic BRC fundus lesions, but 7/7 patients
in the delayed-treatment group displayed typical
lesions. At last follow-up, 5/6 early-treatment patients
showed no fundus lesions, and 6/7 delayed-treatment
patients retained their fundus lesions. At presentation,
all 13 patients exhibited lesions on ICGA. At last
follow-up, ICGA lesions had completely disappeared
in 4/6 early-treatment patients and 3/7 delayed-
treatment patients. Thus, early and sufficiently dosed
inflammation-suppressive treatment can prevent the
appearance of typical BRC fundus lesions. It is
therefore crucial to perform ICGA to detect otherwise
occult stromal choroiditis in suspected BRC cases and
to initiate adequate therapy immediately.
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Indocyanine green angiography  Rice-shaped
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Introduction
Birdshot retinochoroiditis (BRC) is a rare bilateral
retinochoroidal inflammatory disease without known
systemic involvement that mostly appears in Cauca-
sians. It was first described in 1980 by Ryan and
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Maumenee [1] and nearly concomitantly by Gass, who
called the disease vitiliginous choroiditis [2]. The
typical clinical appearance of the full-blown disease is
characterised by low, often subclinical anterior seg-
ment inflammation, vitritis, retinal vasculitis involv-
ing large veins as well as small retinal capillaries [3],
and rice-shaped hypopigmented choroidal lesions [4].
The presence of the HLA-A29 antigen is not only a
very strong supporting finding for BRC diagnosis, but
should probably be considered a diagnostic criterion
because HLA-negative cases are extremely rare [5–9].
BRC is unique in producing dual independent inflam-
matory involvement of the choroid as well as of the
retina, the latter being responsible for disease mor-
bidity and functional impairment due to inflammatory
damage [10, 11].
We previously showed that classical birdshot
fundus lesions are not necessarily present at disease
onset, although they are required for diagnosis by the
published diagnostic research criteria for BRC
(RCBRC) [12, 13]. BRC can be diagnosed during its
subclinical stage when indocyanine green angiogra-
phy (ICGA) indicates occult choroidal lesions, the
presence of characteristic fluorescein angiography
(FA) findings and positive HLA-A-29 testing. Waiting
for the appearance of BRC fundus lesions leads to
significant diagnostic delay [11]. The question arises
whether this diagnostic delay affects the long-term
course of BRC; the necessity of immediate therapy
was not highlighted in older publications because
BRC was considered to have little response to
corticosteroids or immunosuppressives [1, 2, 14–16],
but the main reason for under-treatment was the fact
that visual acuity, rather than retinal function was used
to make treatment decisions. Indeed, for too long the
functional criterion for treatment was (erroneously)
visual acuity and not visual field [17]. However, more
recent reports provide evidence that the functional
outcome of treated BRC patients is superior to non-
treated patients, and studies attempting to determine
the best possible treatment schemes have been
conducted [18, 19]. Unfortunately, there is no univer-
sally accepted and applied treatment. Therefore, it is
critical to assess the long-term follow-up of BRC
patients in terms of various monitoring and treatment
approaches.
We previously reported the beneficial use of
ICGA for monitoring subclinical choroidal inflamma-
tion in the subacute and convalescent stages of
Vogt–Koyanagi–Harada (VKH) disease [20–22]. We
and others demonstrated that even if no inflammation
was clinically apparent in VKH disease, ICGA detected
occult choroidal stromal lesions that indicated smoul-
dering inflammation [23]. We and others assumed that
this subclinical inflammation is the origin of sunset glow
fundus (SGF), often described as part of the natural
course of VKH disease [20, 24, 25]. We also showed that
if inaugural VKH disease is treated early and for a
sufficiently long period with sufficiently high doses of
inflammation-suppressive therapy (IST), SGF can be
avoided [20]. BRC is a stromal choroiditis like VKH
disease, and hence it is reasonable to assume that similar
management strategies might be applied to both
diseases. BRC fundus lesions might be prevented in
the same fashion that SGF can be avoided in VKH
disease, as long as early, vigorous, and prolonged IST is
given.
The aim of this study was to investigate the long-
term follow-up of BRC patients in terms of the impact
of early, vigorous, and prolonged IST on the evolution
of ICGA signs and on the BRC phenotype in terms of
its fundus appearance.
Methods and patients
This was a single-centre, retrospective case review of
all patients with an ocular inflammatory disease seen
at the Centre for Ophthalmic Specialized Care (COS),
Lausanne, Switzerland, between 1995 and 2012. This
study was performed in accordance with the Declara-
tion of Helsinki.
All patients underwent a complete ophthalmological
work-up routinely applied to patients with posterior
uveitis. Routine examinations included Snellen best-
corrected visual acuity (BCVA) testing, slit-lamp
examination, applanation tonometry, and funduscopy
in mydriasis. In addition, at each major visit, a complete
set of investigational procedures was performed that
included laser flare photometry, computerised visual
field testing, microperimetry (when available), optical
coherence tomography (when available), fundus pho-
tography, and dual FA and ICGA.
Patients with the diagnosis of BRC were identified.
As published earlier [11], our diagnostic criteria for
BRC included vitritis and retinal vasculitis in either or
both eyes, visual-field anomalies in either or both eyes,
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stromal choroiditis as evidenced by ICGA in both eyes,
and the presence of the HLA-A29 antigen. An
additional, but not obligatory, criterion was the pre-
sence of rice-shaped, depigmented ‘birdshot lesions’.
Patients with available initial and final follow-up
fundus photography, ICGA, and a follow-up[3 years
were included.
Treatment was proposed in cases with visual field
disturbance. This treatment rarely consisted of sub-
Tenon’s injections when unilateral functional deficit
was present. In cases with bilateral decreased visual
function (visual field or visual acuity), therapy was
increased to dual systemic oral corticosteroids and
immunosuppressants (1–2, ±biologicals) with subse-
quent tapering of steroids over 4–6 months to no
treatment or a dosage\10 mg/day.
Treatment delay was calculated for each patient, and
patients were categorised into two groups—treatment
delay of \10 months (early-treatment group) and
treatment delay of [10 months (delayed-treatment
group). Most patients in the latter group were treated
late because of diagnostic delay and/or because they
declined immediate treatment after diagnosis. Mean
diagnostic delay and mean treatment delay were
calculated for both groups.
Fundus photographs and ICGA frames from the
initial visit and from the last follow-up visit (while the
patient was still under immunosuppressive therapy)
were assessed independently by two investigators
(PBK and CPH), who were blinded to the name of the
patient. If there was disagreement, a third observer
(MP) was asked to interpret the fundus photographs
and ICGA pictures to reach a decision.
Fundus photographs were evaluated for the pre-
sence of at least three circumpapillary, typical, rice-
shaped birdshot lesions in one eye, inferior or nasal to
the optic disc; these lesions were required for the
diagnosis of BRC, particularly as suggested by the
RCBRC. When lesions were present, fundus appear-
ance was scored as mild (\6 lesions; grade 1),
moderate (6–10; grade 2), or severe ([10 lesions;
grade 3). Average fundus scores were compared in
both groups. Patient phenotypes (‘typical fundus
lesions’ meeting the RCBRC system or ‘no fundus
lesions’) were recorded in both groups at presentation
and at the last follow-up visit.
ICGA pictures were evaluated for the presence of
hypofluorescent dark dots (HDDs) and fuzziness of
choroidal vessels. ICGA scores were established
according to the following grading scores—\5 HDDs
in both eyes and no fuzziness of choroidal vessels
corresponded to grade 0 (some hypofluorescent
lesions in the absence of fuzziness were tolerated to
eliminate hypofluorescence due to scars or to non-
birdshot lesions); 5–10 lesions bilaterally corre-
sponded to grade 1, which could be upgraded to grade
2 in cases with extensive fuzziness; 16–30 lesions
bilaterally corresponded to grade 2, which could be
upgraded to grade 3 in cases with extensive fuzziness
of the choroidal vessels or downgraded to grade 1 in
the absence of significant fuzziness;
[30 lesions bilaterally corresponded to grade 3,
which could be downgraded to grade 2 in the absence
of significant fuzziness of the choroidal vessels.
Average scores were compared in both groups.
The proportion of patients with BRC lesions and
those without lesions at the last follow-up was
compared in both groups using Fisher’s exact test.
Differences in mean diagnostic delay and mean
treatment delay were compared between groups.
Differences in the mean scores of BRC lesions and
differences in mean ICGA scores were compared
between groups and between the first visit and the last
follow-up visit in both groups. Student’s t test was
used for all of these statistical comparisons.
Results
Demographics
Out of 1,504 new patients with ocular inflammatory
conditions who were seen between 1995 and 2012, 25
patients (1.66 %; 19 female, 6 male) were diagnosed
with BRC; 13 of these patients had sufficient data, met
the inclusion criteria and could be considered for the
study (0.86 %; 8 female, 5 male; Table 1). All patients
were Caucasian. The mean patient age at BRC onset
was 50.4 ± 7.7 years. All patients tested positive for
the HLA-A29 antigen.
Six patients had a treatment delay of\10 months since
the first symptoms were recorded. The mean diagnostic
delay for these patients was 5.83 ± 2.7 months and the
mean treatment delay was 6.5 ± 3.1 months. Seven
patients had a treatment delay of [10 months, with a
mean diagnostic delay of 25.71 ± 11.6 months and a
mean treatment delay of 51.14 ± 32.1 months. The
length of follow-up after initiation of therapy did not
Int Ophthalmol (2014) 34:563–574 565
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differ between groups (10.3 ± 3.6 years in the early-
treatment group and 10.14 ± 5.4 years in the delayed-
treatment group).
Out of 13 patients, only 8 displayed ‘typical’
birdshot lesions at presentation according to the
RCBRC system. Five patients lacked fundus lesions;
all of these patients belonged to the early diagnosis/
early treatment group.
BRC fundus lesions
At presentation, 5/6 patients in the early treatment
group exhibited no characteristic BRC fundus lesions,
with a fundus score of 0.5 ± 1.2. In contrast, 7/7
patients in the delayed-treatment group had typical
BRC fundus lesions; all these lesions were scored as
grade 3 and the mean fundus score of this group was
3 ± 0, which was significantly higher than the early-
treatment group (p \ 0.0066).
At the last follow-up, 5/6 patients in the early-
treatment group had no fundus lesions. An illustra-
tive case of such disease evolution is shown in
Fig. 1. The lesions resolved and were no longer
visible in one patient (Fig. 2), whereas another
patient developed lesions despite treatment. In the
early-treatment group, fundus score at the last
follow-up remained low (0.33 ± 0.8) and was not
significantly different from the pre-treatment score
(p = 0.22).
At the last follow-up, 6/7 patients in the delayed-
treatment group retained their fundus lesions, with a
slightly lower fundus score of 2.71 ± 0.7 that was not
significantly lower than the pre-treatment score of
3 ± 0 (p = 0.17). This observation indicates that
most lesions already had an irreversible component
with permanent depigmentation that treatment did not
affect (Fig. 3). In one patient, the BRC fundus lesions
regressed, became faint, and no longer met the
RCBRC criteria.
Taken together, these results demonstrate that only
1/6 patients in the early-treatment group developed
characteristic BRC fundus lesions at the end of follow-
up; 5/6 patients never developed rice-shaped BRC
fundus lesions. Six out of seven patients in the delayed
treatment-group exhibited typical BRC fundus lesions
at the end of follow-up. This difference was statisti-
cally significant (two-tailed p \ 0.0292) and was
associated with a positive predictive value of 0.83
for not finding lesions with early treatment and a
negative predictive value of 0.85 for finding lesions
with delayed treatment (Fisher’s exact test).
ICGA data
At presentation, all 13 patients displayed lesions
(HDDs and fuzziness of the choroidal vessels) on
ICGA, with a maximal grading of 3 for all patients (a
mean score of 3 for the entire cohort and for both
subgroups).
At the last follow-up, ICGA lesions had completely
disappeared in 4/6 patients in the early-treatment
group, with a mean angiographic score of 0.66 ± 1.03,
which was significantly lower than the score of
3.0 ± 0 before treatment (p \ 0.0003). Similarly,
ICGA lesions had disappeared in 3/7 patients in the
delayed-treatment group at the last follow-up; the
mean angiographic score decreased to 0.71 ± 0.7,
which was significantly lower than the score at
presentation of 3.0 ± 0 (p \ 0.0007). Sometimes it
was difficult to attribute HDDs to active lesions or to
scars that were not indicative of activity. This
difficulty pertains to all stromal choroiditis entities,
as we previously described for VKH disease [26].
Case illustrations
Case 1 (patient 6, early-treatment group, no BRC
fundus lesions before IST, no lesions after IST, some
persistent ICGA activity; Fig. 1)
A male patient, aged 46 years at treatment onset, was
diagnosed with BRC 9 months after the occurrence of
visual disturbance consisting of a subjective decrease
in visual acuity, dimness of vision, and floaters.
Systemic IST was prescribed due to bilateral visual
field defects that were noted on Octopus perimetry
(Octopus, Haag-Streit, Bern, Switzerland). At presen-
tation, BCVA was 1.0 in both eyes and laser flare
photometry indicated a subclinical aqueous flare of 7.0
ph/ms in the right eye and 9.1 ph/ms in the left eye;
there was a bilateral vitritis amounting to 2? cells
(arbitrary slit-lamp score used in our institution), and
the fundus was fuzzy but otherwise devoid of lesions
(Fig. 1a, left sextet of images). Octopus perimetry
revealed a decreased mean defect as well as several
focal scotomas. FA showed bilateral retinal vasculitis
of the large veins and diffuse retinal hyperfluorescence
due to capillary leakage, disc hyperfluorescence, and
Int Ophthalmol (2014) 34:563–574 567
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macular oedema (Fig. 1b, left sextet of images). ICGA
indicated numerous HDDs as well as pronounced
fuzziness of the choroidal vessels, yielding an angio-
graphic score of 3 (Fig. 1c, top two images).
After 5 years of combined Myfortic (mycophen-
olic acid, 720 mg twice per day) and Remicade
(infliximab, 5 mg/kg every 8 weeks) therapy, BRC
fundus lesions did not appear (Fig. 1a, right sextet of
568 Int Ophthalmol (2014) 34:563–574
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images). FA results improved markedly, with resolu-
tion of vasculitis, macular oedema, and optic disc
hyperfluorescence (Fig. 1b, right sextet of images).
The ICGA results normalised, with nearly total fading
of the HDDs and some persistent fuzziness of vessels,
with an angiographic score of 1 (Fig. 1c, bottom
images). On follow-up using ICGA frames, it is
sometimes difficult to determine whether HDDs are
caused by choroidal scars or by active lesions,
although the absence of fuzziness of the choroidal
vessels suggests that active HDDs are not present [26].
Case 2 (patient 2, early-treatment group, fundus
lesions present at entry that resolved, ICGA signs
resolved; Fig. 2)
A female patient, aged 54 years, was referred 9 months
after the onset of ocular symptomatology consisting of
dimness of vision and myodesopsias. She was diagnosed
as BRC based on her FA and ICGA findings, her tubular
visual fields, and positive HLA-A29 antigen. Despite
relatively early diagnosis, fundus examination already
revealed typical BRC fundus lesions (Fig. 2a, left sextet
of images) associated with the usual FA signs of
vasculitis of the large retinal veins, diffuse retinal
exudation/leakage from the small capillaries, and disc
hyperfluorescence. ICGA showed extensive choroidal
involvement, with many HDDs and fuzziness of the
choroidal vessels (Fig. 2b, left sextet of images).
IST maintenance therapy consisted of azathioprine
(2.0 mg/kg) and low-dose prednisone after tapering
from an initial dose of 1 mg/kg. After 13 years of
treatment, not only did the ICGA signs resolve
completely (Fig. 2b, right sextet of images), but the
BRC fundus lesions resolved as well (Fig. 2a, right
sextet of images).
Case 3 (patient 12, late-treatment group, fundus
lesions present before treatment that persisted at last
follow-up, resolution of ICGA signs; Fig. 3)
A 61-year-old female patient had been followed
elsewhere, but treatment was withheld for 57 months.
When she presented, she showed typical bilateral
birdshot lesions on fundus examination (Fig. 3a, left
sextet of images). FA findings were characterized by
massive intraretinal exudation/leakage from the reti-
nal capillaries leading to no staining of the large veins
due to the lack of fluorescein concentration in the
venous circulation, an angiographic feature often seen
in BRC [3]. ICGA indicated a bilateral grade 3
involvement of the choroid, with numerous HDDs
(Fig. 3b, left sextet of images).
Treatment, which was decided based on visual field
impairment, consisted of dual azathioprine (2.2 mg/kg)
and oral prednisone (40 mg tapered over 4 months).
Discrete BRC fundus lesions were initially present in
both eyes (Fig. 3a, left sextet of images). 6 years later,
the BRC did not show the well-delineated BRC lesions
and became substantially fainter although still present
(Fig. 3a, right sextet of images). In parallel, the HDDs
had completely resolved bilaterally compared to pre-
treatment (Fig. 3b, right sextet of images). This example
of fundus lesions persisting but HDDs resolving indi-
cates that HDDs do not correspond to BRC fundus
lesions, which reflect irreversible stromal depigmenta-
tion, but usually indicate active lesions.
Fig. 1 Patient 6, a male who was 43 years old at diagnosis, with
a diagnostic delay of 9 months and a treatment delay of
10 months (right eye). a The left sextet of fundus images shows
a fundus at presentation that is slightly fuzzy, but no BRC
fundus lesions are visible. The right sextet of images reflects the
fundus after 5 years of IST; the fundus has decreased fuzziness
and persistent absence of BRC fundus lesions. b The left sextet
of FA images was taken at presentation and displays vasculitis
of the large vessels, diffuse retinal exudation from the small
retinal vessels, cystoid macular oedema, and disc hyperfluores-
cence. The right sextet of frames reveals almost complete
regression of all FA signs after 5 years of IST. c ICGA frames at
presentation (top two frames) show numerous HDDs and
fuzziness of the choroidal vessels. After 5 years of IST (bottom
frames), these typical HDDs have disappeared, but faint areas of
hypofluorescence and persistent fuzziness remain visible
Fig. 1 continued
b
Int Ophthalmol (2014) 34:563–574 569
123
Fig. 2 Patient 2, a female who was 54 years old at diagnosis,
with a diagnostic delay of 9 months and a treatment delay of
10 months (right eye). a The left sextet of fundus images shows
typical BRC fundus lesions with a fuzzy fundus view. After
13 years of IST, the fundus is less fuzzy and fails to display
typical BRC fundus lesions (right sextet of figures). b ICGA
frames at presentation (left nine frames) reveal many HDDs with
total fuzziness of the choroidal vessels, which cannot be
distinguished. The right nine frames indicate an ICGA
appearance within normal limits, with resolution of the HDDs
and a normal aspect of the large choroidal vessels
570 Int Ophthalmol (2014) 34:563–574
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Discussion
Since the first descriptions by Ryan and Maumenee [1]
and by Gass [2], the hallmark sign of BRC has been the
characteristic rice-shaped depigmented fundus lesion.
Ryan and Maumenee named BRC after these lesions,
which ‘frequently have the pattern seen with birdshot
in the scatter of a shotgun’. These authors, and
subsequently others, described a striking clinical sign
of an already-advanced stage of a disease that had not
been treated adequately or had not been treated at all
because the disease could not be diagnosed at the pre-
BRC fundus lesion stage. This sign served as the basis
of BRC diagnosis for the next 33 years.
The peculiar characteristic of BRC is the dual,
parallel, but unrelated inflammation of the retina and
the choroid [10]. Retinal involvement is best illus-
trated by FA, which in the active exudative stage of the
disease shows diffuse capillary leakage causing
diffuse retinal oedema with prominent diffuse hyper-
fluorescence, sheathing of the larger veins, and
posterior pole oedema, sometimes with cystoid mac-
ular oedema and disc hyperfluorescence [11]. The
corollary to this oedematous retinitis is the retinal
thickening seen on optical coherence tomography
during the exudative phase of the disease [27].
Choroidal inflammation is characterised by a stromal
choroiditis that precedes the classical BRC fundus
lesions by months or even years, but remains unde-
tected unless ICGA is performed.
We previously reported that ICGA allows the
detection of occult choroiditis and, together with
compatible retinal findings and the presence of HLA-
A29 antigen, leads to early diagnosis of BRC before
typical fundus lesions are present [28, 29]. If the
RCBCR had been applied, patients without the typical
BRC fundus lesions would not have been included in
the present investigation.
In this study, we compared the evolution of fundus
appearance and ICGA signs in two groups of BRC
patients receiving IST consisting mostly of C2
immunosuppressive/biological agents. Treatment did
Fig. 3 Patient 12, a female who was 61 years old at presen-
tation, with a diagnostic delay of 6 months and a treatment delay
of 57 months (left eye). a The left sextet of images reveals
typical, although faint, BRC fundus lesions at presentation that
tended to become less visible after 6 years of IST (right sextet of
fundus images). b ICGA frames at presentation (top six frames)
show numerous HDDs that completely resolved after 6 years of
IST (bottom six frames)
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not differ between groups. In one group, treatment was
started early, before the occurrence of BRC fundus
lesions. In the other group, mostly due to delays in
diagnosis, treatment was started after BRC fundus
lesions were already present. We were especially
interested in the evolution of the fundus in patients
treated before the observation of fundus lesions.
To the best of our knowledge, this is the first report
showing that early treatment of BRC nearly com-
pletely prevents the development of BRC fundus
lesions and modifies the clinical phenotype of the
disease. Stromal hypopigmentation of the choroid in
these patients did not develop throughout the course of
a follow-up of[10 years. BRC fundus lesions there-
fore should be considered to be an evolutionary stage,
a complication of the disease when treatment is given
too late or is insufficient, but their apparition should
not be considered obligatory.
‘Regression of birdshot lesions’ was previously
reported by Leder et al. [30], who in fact described
regression of ICGA lesions after treatment was
initiated; they treated ICGA lesions and BRC fundus
Fig. 3 continued
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lesions as equivalent, which cannot be done because
HDDs on ICGA do not correspond to BRC fundus
lesions. Our data show that ICGA signs diminished in
all of our patients, to almost no signs in the early-
treatment group and to very low values in the late-
treatment group, despite the persistence of BRC
fundus lesions in the latter group. This observation
means that HDDs correspond to active inflammatory
lesions that have not yet produced depigmentation and
that are still reversible without causing depigmenta-
tion. Such lesions were described histologically by
Gaudio et al. [31], who indicated that they do not touch
the choriocapillaris–retinal pigment epithelium com-
plex. For BRC fundus lesions, upon digestion of the
stromal pigment islets, a depigmented area is hypoth-
esised to be left behind that consists of areas that do
not produce ICGA signs, because their resolution did
not result in significant fibrosis or scarring. At an early
stage of the disease, when no BRC fundus lesions are
detected, treatment prevents this development, as
shown in our study. This evolution is analogous to
adequately treated VKH disease. We showed that SGF
(which can be considered analogous to BRC fundus
lesions) can be prevented by early, sufficiently dosed,
and prolonged IST. VKH disease, however, is distinct
from BRC because the active and primary inflamma-
tion process is limited to the choroid; retinal inflam-
mation is only secondary to the severe choroidal
inflammation spilling over to the retina and other
neighbouring structures, and successful treatment of
choroiditis will also eliminate inflammation in the
other compartments. In contrast, control over cho-
roiditis is easily achieved in BRC, as demonstrated by
the significant reduction in ICGA score in the two
groups of the present investigation. However, this
control is not sufficient, as there is autonomous retinal
disease that is not secondary to choroiditis [32, 33].
In conclusion, we have demonstrated for the first
time that early and sufficiently dosed IST can prevent
the appearance of typical BRC fundus lesions. It is
therefore crucial to perform ICGA to detect otherwise
occult stromal choroiditis in suspected BRC cases and
to initiate adequate therapy immediately if there is
functional impairment, such as visual field changes.
The validity of the RCBRC system must be seriously
questioned; in addition to its inadequacy for early
diagnosis, we recently demonstrated the presence of
granulomatous keratic precipitates in 3/19 BRC
patients, indicating that this exclusion criterion was
inadequate [34]. If we wish to improve outcomes in
BRC, diagnostic criteria need to be revised and the
main disease-defining criterion of depigmented BRC
fundus lesions must be abandoned for the diagnosis of
incipient early disease. Waiting for this sign to appear,
which is currently necessary for diagnosis, leads to
unwanted delay of treatment.
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